Form 4 for BLFS BIOLIFE SOLUTIONS INC
Accepted 2025-10-17 00:00:00 ET · period of report 2025-10-15 · accession 0000919574-25-006180 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-10-17 | 2025-10-15 | BLFS | Casdin Partners GP, LLC | 10% | S - Sale | $28.55 | -750.0K | 5.96M | -11% | -$21.41M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.001 per share | 2025-10-15 | S | D | 750,000 | $28.55 | 5,957,165 | I Footonote | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $28.50 to $28.8354. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F2) The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. |